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Background: Geriatric screening tools are increasingly implemented in daily practice, especially in the oncology
setting, but also in primary care in some countries such as the Netherlands. Nonetheless, validation of these tools
regarding their ability to predict relevant outcomes is lacking. In this study we evaluate if geriatric screening tools
predict decline in functional status and quality of life after one year, in a population of older cancer patients and an
older primary care population without cancer with a life expectancy of at least six months.
Methods: Older cancer patients and a general older primary care population without a history of cancer (≥70 years)
were included in an on-going prospective cohort study. Data were collected at baseline and after one-year follow-up.
Functional decline was based on the Katz Index and Lawton IADL-scale and was defined as deterioration on one or
more domains. Decline in quality of life was measured using the global health related subscale of the EORTC QLQ-C30,
and was defined as a decline ≥10 points. The selected geriatric screening tools were the abbreviated Comprehensive
Geriatric Assessment, Groningen Frailty Indicator, Vulnerable Elders Survey-13, and G8. We calculated sensitivity,
specificity, predictive values, and odds ratios to assess if normal versus abnormal scores predict functional decline and
decline in quality of life.
Results: One-year follow-up data were available for 134 older cancer patients and 220 persons without cancer.
Abnormal scores of all screening tools were significantly associated with functional decline. However, this was only true
for older persons without cancer, and only in univariate analyses. For functional decline, sensitivity ranged from 54% to
71% and specificity from 33% to 66%. For decline in quality of life, sensitivity ranged from 40% to 67% and specificity
from 37% to 54%.
Conclusion: In older persons with a relatively good prognosis, geriatric screening tools are of limited use in identifying
persons at risk for decline in functional status or quality of life after one year. Hence, a geriatric screening tool cannot
be relied on in isolation, but they do provide very valuable information and may prompt physicians to also consider
different aspects of functioning.
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Given the current demographic changes, and because
cancer is mainly a disease of older persons, the number
of older cancer patients is rising [1]. Currently, almost
half of cancer survivors are aged 70 years or older [2].
As such, primary, as well as secondary care providers
will be increasingly confronted with this growing group
of patients.
Older cancer patients form a very heterogeneous group
of patients. Among persons aged 70 years and above, there
is a substantial variety in levels of fitness, comorbidity, and
physiological reserve. Hence, treatment decisions related
to cancer (oncologist) or general health (primary care)
should not be based on chronological age alone. There-
fore, clinicians have been searching for ways to obtain a
better view on the global health status and reserve capaci-
ties of older cancer patients [3]. Currently, one’s global
health status and reserve capacities are best estimated by a
geriatric assessment, which has been defined as a multidis-
ciplinary evaluation of an older individual’s functional
status, comorbidity, cognition, psychological status, social
support, nutritional status and review of the patient’s
medications [4,5]. Reasons for a geriatric assessment may
vary, depending on the treatment decisions that have to be
made. In oncology, the rationale behind a geriatric assess-
ment is to assess if, for a given patient, anti-cancer treat-
ment would do more good than harm [3,6]. Oncologists
want to answer the following questions: what is the life ex-
pectancy of this patient; will the tumour influence overall
survival and Quality of Life (QoL), or are other competing
causes of death/disability of more importance? For gener-
alists, such as general practitioners (GPs), the rationale be-
hind a geriatric assessment is to assess how illness impacts
functioning and what the social and medical needs are in
order to develop a plan for treatment and follow-up, to
manage the problems that were identified, and to prevent
dependency [7].
Unfortunately, a geriatric assessment is very time con-
suming. Therefore, a two-step approach using geriatric
screening tools has been suggested [8]. Numerous geriat-
ric screening tools have been developed and especially in
the oncology setting, these are increasingly implemented
in daily practice. Also in some countries such as the
Netherlands, geriatric screening tools are also imple-
mented in primary care (see for example [9]). The ma-
jority of studies have focused on assessing their ability to
identify patients who might benefit from a full geriatric
assessment [10]. A recent update of the SIOG (Inter-
national Society of Geriatric Oncology) recommenda-
tions showed that screening tools are indeed useful in
order to identify those patients in need of a full geriatric
assessment [11]. However, the predictive value of these
screening tools remains open to debate. In older cancer
patients, only a handful of studies focussed on theirability to predict mortality and treatment toxicity [12],
only one study has focused on their ability to predict
functional decline [13], and to our knowledge there are
no studies that evaluated decline in QoL, although it is
increasingly recognised that functional status and QoL
are relevant outcomes, especially for older patients. As
shown by others, adequate validation of these tools with
respect to their value to predict functional decline and
decline in QoL is lacking [10,13]. In primary care, the
prediction of functional decline has received slightly
more attention compared to older cancer patients but
nonetheless the predictive abilities of several geriatric
screening tools remains open to debate.
Hence, the aim of this study is to evaluate the value of
four geriatric screening tools to predict functional de-
cline and decline in QoL in a population of older cancer
patients with a considerable life expectancy (>6 months),
as especially in these patients functional decline and
decline in QoL might be relevant outcomes. The time-
frame of this study is a one-year period. This is a very
relevant time frame for primary care as for cancer pa-
tients, this often corresponds with the transition from
secondary to primary care, i.e. the time when the general
practitioner becomes the first contact person again. Previ-
ous studies have shown that the role of general practi-
tioners in cancer (after) care will become more prominent
due to the increasing numbers of older cancer patients,
and the shift from inpatient to ambulatory care [14-16].
Furthermore, we also aim to evaluate the predictive
value of these tools in a general older primary care popula-
tion without a history of cancer, because functional decline
and decline in QoL are also relevant outcomes in this
population and geriatric screening tools are also increas-
ingly being implemented in primary care [17,18].
Methods
Design and study population
The data for this study were collected as part of the
KLIMOP-study (Dutch acronym for “Kanker bij Limburgse
en Vlaams-Brabantse Ouderen Project”) [19]. KLIMOP is
an on-going observational cohort study of older cancer
patients and a general older primary care population with-
out a history of cancer (except non-melanoma of the skin),
aged 70 years and above. The focus of this study is the
long-term wellbeing of older cancer patients.
For the current study we selected only cancer patients
with a new diagnosis of breast or colorectal cancer, and
cancer stage I – III. We made this choice in order to
have a more homogeneous sample for the analysis. They
were recruited through seven hospitals in Belgium and
the Netherlands, within three months after cancer diagno-
sis. Older patients without cancer were recruited through
general practices in Belgium and the Netherlands in the
same regions as the cancer patients. General practitioners
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no history of cancer) to participate until 20 patients per
general practitioner had agreed to participate.
Exclusion criteria for older cancer patients as well as
persons without cancer were the inability to speak
Dutch, a formal diagnosis of dementia, and an estimated
life expectancy less than six months. For this study we
present data of all patients included in the study be-
tween June 2010 and August 2012, who also participated
in the data collection after one year.
Data collection
Methods of data collection and management were
identical in both groups. Data were collected through
personal interviews or self-administered questionnaires,
at baseline and at one-year follow-up. Data collection
included socio-demographic information, medical infor-
mation (number of medicines, type of cancer, cancer
stage, and anti-cancer treatments received in the first
year after diagnosis), functional status, a QoL question-
naire, and four geriatric screening tools. For the ques-
tionnaires such as functional status and QoL, people are
asked to indicate for each statement the extent to which
they apply their situation of the past week.
Dependent variables
Decline in functional status
Functional status was measured by Activities of Daily
Living (ADL) using the Katz Index [20] and by Instrumen-
tal Activities of Daily Living (IADL) using the Lawton
IADL-scale [21]. The Katz Index consists of six items
(bathing, dressing, toileting, transferring, continence and
feeding); each item was scored as dependent versus inde-
pendent. The total sum score ranges from 0 (dependent)
to 6 (independent). The Lawton IADL-scale consists of
eight items in women (ability to use the telephone, shop-
ping, cooking, housekeeping, doing laundry, taking own
medication, making transports, and ability to handle
finances), and only five items in men, because cooking,
housekeeping and doing laundry are not always applicable
to men. Each item was scored as dependent versus inde-
pendent. The total sum score ranges from 0 (dependent)
to 8 (independent) for women, and from 0 (dependent) to
5 (independent) for men. Functional impairment was de-
fined as dependency on at least one domain of ADL (score
<6) or IADL (a score <8 from women or <5 for men).
Functional decline was defined as deterioration on at least
one domain of ADL or IADL compared to baseline
(decline ≥1 point).
Decline in quality of life (QoL)
QoL was measured with the European Organization for
Research and Treatment of Cancer Quality of Life Ques-
tionnaire C30 version 3 (EORTC QLQ-C30) [22]. Thequestionnaire consists of 30 questions, which corres-
pond to five functional scales, three symptom scales, six
single-item scales, and a global health related QoL scale.
In this study, we only report the global health related
QoL, from this point forward indicated as QoL. QoL is
assessed by two Likert scales, ranging from one to seven,
that measure a person’s perception on the health status
and QoL of the past week. Based on the EORTC QLQ-
C30 manual, QoL was recoded in a score ranging from 0 –
100, with higher scores representing better QoL [23]. The
QoL subscale has high internal consistency with Cron-
bach’s alpha ranging between 0.82 and 0.89 [22]. In this
study Cronbach’s alpha was 0.78 for older cancer patients
and 0.76 for older persons without cancer. Decline in QoL
was defined as a difference ≥10 points, which indicates a
clinically important change [24].
Independent variables
The geriatric screening tools included the abbreviated
Comprehensive Geriatric Assessment (aCGA), the G8, the
Groningen Frailty Indicator (GFI), and the Vulnerable
Elders Survey-13 (VES-13). In one hospital, data collection
was integrated in a routine geriatric assessment, and
therefore, data collection was slightly different in this
hospital; here QoL, GFI and VES-13 were not assessed.
Hence, for 35 older cancer patients no data were available
for these measurements. We always indicate the number
of patients included in the analyses and a detailed flow-
chart of the patient population is provided in Figure 1.
The abbreviated comprehensive geriatric assessment
(aCGA)
The aCGA was developed as a screening tool to identify
older cancer patients who might benefit from an entire
geriatric assessment. The aCGA was based on a chart re-
view of more than 500 cancer patients [25,26]. The selec-
tion of items was based on psychometric criteria; those
items within each scale that showed the highest item-to-
total correlation were selected. As such, the aCGA in-
cludes four items from the 15-item Geriatric Depression
Scale, three items from ADL, four items from IADL, and
four items from the Mini Mental State Examination. A
cut-off value was identified for each domain, indicating
whether a more elaborate assessment was needed for that
domain: ≥1 for the selected items of ADL and IADL; ≤6
for the items of the Mini Mental State Examination; and
≥2 for the items of the 15-item Geriatric Depression Scale
[27]. In this study, we operationalized abnormal scores on
the aCGA as impairment on at least one domain; this is in
agreement with previous studies [27,28].
The G8
The G8 was designed to identify older cancer patients
who might benefit from an entire geriatric assessment
KLIMOP-study
Older cancer patients Older persons without cancer
Included:
Between June 2010 and August 2012:
Excluded:
Analysed:
Subgroup of patients with no measurement and missing values:
N = 323
Lost to follow-up: N = 79 
Skipped one-year follow-up: N = 20 
Received a diagnosis of cancer: N = 4
Total: N = 220
Deceased: N = 5
With one-year follow-up interview: N = 215
 Excluding patients with missing values: N = 187 
N = 180
Lost to follow-up: N = 37 
Skipped one-year follow-up: N = 9 
Total: N = 134
Deceased: N = 9
With one-year follow-up interview: N = 125
 Excluding patients with missing values: N = 115 
 Excluding patients with no measurement and 
missing values for QoL, Ves-13 and GFI: N = 67 
Figure 1 Flow-chart: population of the KLIMOP-study.
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nutritional status, weight loss, body mass index, mobil-
ity, psychological status, number of medications, and
self-perception of health [29]. The maximum score is 17
points. An abnormal score on the G8 was defined by the
original cut-off value of ≤14.
The Groningen Frailty Indicator (GFI)
The GFI was developed as a short screening tool, aiming
to identify patients that have diminished reserves in one
or more of the fundamental domains of functioning and
was originally tested in a sample of hospital inpatients,
nursing home residents, and community-dwelling elderly
[30]. It has been widely used in older cancer patients
[10], as well as older primary care populations [18]. The
GFI assesses mobility, assistance needed with toileting
and shopping, physical fitness, poor hearing and vision,
medicine use, weight loss, and complaints about mem-
ory, feelings of isolation, depression, and anxiety [30]. It
consists of 15 questions with a maximum score of 15
points. Abnormal score for the GFI was defined by the
original cut-off value of ≥4.
The Vulnerable Elders Survey-13 (VES-13)
The VES-13 was originally developed for identifying
community-dwelling vulnerable older people at increased
risk of death or functional decline [31], but has also been
frequently used in older cancer patients [10]. The VES-13is a simple 13-item screening tool including questions
about older peoples’ ability to perform six physical and five
functional activities, their self-rated health, and their age
[31]. The maximum score is 10 points; an abnormal score
was defined by the original cut-off value of ≥3.
Ethics
The Ethical Review Board of KU Leuven and UZ Leuven
(S52097 – ML6279) and the Maastricht University Med-
ical Centre (NL31414.068.10) approved the study proto-
col. The study was conducted in compliance with Good
Clinical Practice guidelines Procedures, the principles of
the Declaration of Helsinki (version October 2008) and
the Belgian (law of 7 may 2004 concerning clinical trials
with humans) and Dutch (Medical Research Involving
Human Subjects Act and Personal Data Protection Act)
laws. All patients signed informed consent.
Analysis
Sociodemographic and clinical characteristics of the study
population are presented as the mean and standard devi-
ation (SD) for continuous variables and as numbers and
proportions for categorical variables. Comparisons be-
tween different groups (older cancer patients versus older
persons without cancer) were performed using t-test for
continuous data and the chi square test for categorical
data. Furthermore, we compared persons that were
included and excluded from analyses. Throughout all
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without cancer as separate groups, and a p value < 0.05
was considered to be statistically significant.
We calculated sensitivity, specificity, predictive values,
and area under the receiver operating curve (AUC) with
their 95% confidence intervals (CI) to assess if normal
versus abnormal scores on the geriatric screening tools
are able to predict functional decline and decline in
quality of life after one year. Furthermore, Odds Ratios
(OR) and corresponding 95% Confidence Intervals (CI)
were calculated to compare the risk for decline in func-
tional status and QoL after one-year follow-up in persons
with normal versus abnormal scores on the geriatric
screening tools. Univariate and multivariate logistic regres-
sion models were used. In multivariate models age, sex,
and number of medicines were included as covariables.
For cancer patients also cancer stage, cancer type, and
treatment type were included as covariables.
As a sensitivity analysis, we repeated the analyses, in-
cluding participants who died during one-year follow-
up. In this case, mortality, defined as death within one
year after baseline evaluation, was included as functional
decline or decline in QoL. For some patients data for
the geriatric screening tools were missing. Therefore we
performed a sensitivity analysis to assess the influence of
these missing values, making a worst- and best-case sce-
nario by imputing missing values either as a normal or
abnormal score. Furthermore, the proportion of women
in the group of cancer patients was higher as compared
to the primary care population without cancer due to
the inclusion of breast cancer patients. As a sensitivity
analysis, we repeated the analyses for women separately.
We also aimed to assess the influence of our operationa-
lization of functional decline. Therefore, we repeated the
analyses for decline on ADL and IADL separately; de-
cline on ADL was defined as deterioration on one do-
main of the ADL scale (decrease ≥1 point) and decline
on IADL was defined as deterioration on one domain of
the IADL scale (decrease of ≥1 point).
Statistical analyses were performed using the STATA
statistical software package version 11 (StataCorp LP,
College Station, TX).
Results
Population
In total 503 participants were recruited. For 354 (70%)
participants follow-up data were available, baseline
characteristic are presented in Table 1. All patients were
Caucasian. The mean age of cancer patients was com-
parable to the mean age of persons without cancer
(77.10 and 78.13 respectively). The proportion of women
was higher in the cancer group compared to older per-
sons without cancer, due to the recruitment of breast
cancer patients (p < 0.01). Between 42% and 64% of oldercancer patients had abnormal scores on the screening
tools, and between 45% and 56% of older persons with-
out cancer had abnormal scores on the screening tools
(see Table 1). The prevalence of abnormal scores was
comparable in persons with and without cancer for all
screening tools except for the aCGA (p < 0.04). Seventy-
two percent of older cancer patients and 65% of persons
without cancer were functionally impaired at baseline
(p = 0.12). The baseline mean QoL was significantly lower
for older cancer patients compared to older persons
without cancer (p < 0.01).
Follow-up
During the one-year follow-up period, 9 older cancer
patients and 5 persons without cancer died (p < 0.01). Of
the 503 participants, 116 (23%) were lost to follow-up
and 29 (6%) patients skipped data collection at one-year
follow-up (see Figure 1). Patients who skipped data collec-
tion were still willing to participate in future follow-up
visits (e.g. at three years follow-up). Reasons for skipping
the interview at one-year follow-up were personal prob-
lems (e.g. loss of a spouse), health problems (e.g. cancer
recurrence), and other (e.g. too busy). The percentage of
older cancer and persons without cancer that were lost to
follow-up or skipped data collection at one-year follow-up
was comparable (p = 0.93). Furthermore, cancer patients
with one-year follow-up data were similar to those without
follow-up data with respect to age, sex, living conditions,
cancer type, and functional status at baseline. Only for
cancer stage, the proportion of excluded cancer patients
with stage II cancer was lower, and the proportion with
stage III cancer was higher, as opposed to included cancer
patients (p < 0.04). Also for person without cancer, baseline
characteristics were comparable for those with and with-
out one-year follow-up (see Additional file 1: Table S1).
Predictive value of geriatric screening tools
Functional decline
After one-year follow-up, 58% of older cancer patients ex-
perienced functional decline, compared to 43% of persons
without cancer (p < 0.01). Abnormal scores at baseline for
all four geriatric screening tools were significantly associ-
ated with functional decline after one year, but only
among persons without cancer, and only in univariate ana-
lyses. In multivariate analyses, only abnormal score on the
VES-13 was significantly associated with functional de-
cline in older persons without cancer (ORVES-13 2.83, 95%
CI: 1.35 – 5.95). The predictive properties of all screening
tools were poor with sensitivity ranging between 54% and
71% for functional decline (see Table 2). Specificity ranged
between 33% and 66%. The positive predictive value
ranged between 49% and 65% and the negative predictive
value ranged between 43% and 72%. The AUC ranged be-
tween 0.50 and 0.64, hence, also the ability of the selected
Table 1 Baseline population characteristics
Older cancer
patients
Older persons
without cancer
N = 134 N = 220
N % N % p value
Age: mean (SD) 77.10 (5.11) 78.13 (5.47) 0.08
Gender 0.001
Male 28 21% 82 37%
Female 106 79% 138 63%
Living conditions 0.17
Alone 44 33% 72 33%
With partner 76 57% 137 62%
With friends/family 6 4% 7 3%
Institutionalised 8 6% 4 2%
Cancer site
Breast 93 69%
Colorectal 41 31%
Cancer treatment
Surgery 125 93%
Chemotherapy 39 29%
Radiotherapy 70 52%
Hormonal therapy 53 40%
Targeted therapy 4 3%
Missing 3 2%
Cancer Stage
I 22 16%
II 72 54%
III 18 13%
Missing 22 16%
Geriatric screening tools
aCGA: Abnormal score 86 64% 123 56% 0.04
Missing 12 12
G8: Abnormal score 84 63% 119 54% 0.10
Missing 3 4
GFI: Abnormal score 42 42% 98 45% 0.58
Missing 17 14
Not measureda 35 /
VES-13: Abnormal score 48 48% 109 50% 0.92
Missing 5 4
Not measureda 35 /
Functional impairmentb 97 72% 141 65% 0.12
Missing 0 0
ADL impairment 69 51% 87 41% 0.06
IADL impairment 75 56% 113 51% 0.40
Functional decline 73 58% 93 43% 0.01
Table 1 Baseline population characteristics (Continued)
QoL: mean (SD)a 69.93 (19.30) 75.91 (17.84) 0.01
Decline in QoL 15 23% 50 30% 0.48
Missing 7 1
Not measureda 35 /
Abbreviations: aCGA abbreviated Comprehensive Geriatric Assessment, GFI
Groningen Frailty Indicator, VES-13 Vulnerable Elders Survey-13, ADL activities
of daily living, IADL instrumental activities of daily living, QoL Quality of Life.
aIn one hospital, data collection was integrated in a routine geriatric assessment,
therefore QoL, GFI and VES-13 were not assessed in the 35 older cancer patients
recruited in this hospital. Decline in QoL was defined as a difference ≥10 points.
bFunctional impairment was defined as impairment on at least one domain of
ADL or IADL. Decline in functional status was defined as deterioration on at
least one domain of ADL or IADL compared to baseline.
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that will or will not experience functional decline is poor.
QoL
Between baseline and one-year follow-up, 23% of older
cancer patients and 30% of older persons without cancer
experienced decline in QoL (p = 0.24). None of the geri-
atric screening tools was associated with a decline in
QoL. Also for QoL, the predictive properties of all
screening tools were poor with sensitivity ranging be-
tween and 40% and 67% (see Table 2). Specificity ranged
between 37% and 54%. The positive predictive value
ranged between 18% and 27% and the negative predict-
ive value ranged between 67% and 80% for decline in
QoL. The AUC ranged between 0.42 and 0.53 for decline
in QoL.
Sensitivity analyses
Results were robust for sensitivity analyses and did not
change when mortality was included as endpoint for
functional decline and decline in QoL (see Additional
file 2: Table S2), nor when missing values for geriatric
screening tools were imputed either as a worst- or best-
case scenario (see Additional file 2: Table S3), when ana-
lyses were repeated for women only (see Additional file 2:
Table S4), or when the operationalization of functional
decline was altered (see Additional file 2: Table S5).
Discussion
In geriatric oncology as well as in the primary care
setting, geriatric screening tools are increasingly imple-
mented in daily practice. However, firm evidence for
their ability to predict relevant outcomes such as func-
tional decline and decline in QoL is lacking. In the
current study, we showed that the predictive properties
of the geriatric screening tools were poor in a population
of older (cancer) patients with a relatively good progno-
sis. Abnormal scores for the selected geriatric screening
tools were associated with a higher risk of functional de-
cline. However, this was only true in an older primary
Table 2 Diagnostic accuracy of geriatric screening tools to predict decline in functional status and QoL
Sensitivity Specificity Positive
predictive value
Negative
predictive value
Area under
the curve
Univariate logistic
regression
Multivariate logistic
regressionc
N total Se (95% CI) Sp (95% CI) PPV (95% CI) NPV (95% CI) AUC (95% CI) OR (95% CI) OR (95% CI)
Functional declinea
aCGA Cancer patients 115 71% (59% - 82%) 33% (20% - 48%) 59% (47% - 70%) 46% (29% - 63%) 0.52 (0.43 - 0.61) 1.20 (0.54 - 2.67) 0.61 (0.23 - 1.64)
Persons without cancer 187 67% (55% - 78%) 52% (43% - 62%) 49% (39% - 59%) 70% (59% - 80%) 0.60 (0.53 - 0.67) 2.23 (1.22 - 4.09) 1.87 (0.93 - 3.78)
G8 Cancer patients 115 64% (51% - 75%) 37% (23% - 52%) 58% (45% - 69%) 43% (28% - 59%) 0.50 (0.41 - 0.59) 1.02 (0.47 - 2.19) 0.67 (0.28 - 1.65)
Persons without cancer 187 65% (53% - 75%) 57% (47% - 66%) 51% (40% - 61%) 70% (59% - 79%) 0.61 (0.54 - 0.68) 2.38 (1.31 - 4.35) 1.80 (0.90 - 3.60)
GFI Cancer patients 67 54% (37% - 71%) 59% (41% - 76%) 59% (41% - 76%) 54% (37% - 71%) 0.57 (0.45 - 0.69) 1.74 (0.66 - 4.58) 1.23 (0.35 - 4.35)
Persons without cancer 187 58% (46% - 69%) 63% (53% - 72%) 52% (41% - 63%) 69% (59% - 78%) 0.61 (0.53 - 0.68) 2.35 (1.29 - 4.26) 1.83 (0.92 - 3.65)
VES-13 Cancer patients 67 57% (39% - 74%) 66% (47% - 81%) 65% (45% - 81%) 58% (41% - 75%) 0.61 (0.50 - 0.73) 2.55 (0.95 - 6.85) 2.58 (0.59 - 11.22)
Persons without cancer 187 62% (50% - 73%) 66% (56% - 75%) 55% (44% - 66%) 72% (62% - 80%) 0.64 (0.57 - 0.71) 3.11 (1.70 - 5.71) 2.83 (1.35 - 5.95)
Decline in Qolb
aCGA Cancer patients 67 47% (21% - 73%) 37% (24% - 51%) 18% (7% - 33%) 70% (50% - 86%) 0.42 (0.27 - 0.56) 0.50 (0.16 - 1.61) 0.44 (0.10 - 1.91)
Persons without cancer 187 56% (41% - 70%) 45% (36% - 53%) 27% (19% - 37%) 74% (63% - 83%) 0.50 (0.42 - 0.58) 1.02 (0.53 - 1.96) 1.14 (0.55 - 2.39)
G8 Cancer patients 67 67% (38% - 88%) 39% (25% - 53%) 24% (12% - 40%) 80% (59% - 93%) 0.53 (0.39 - 0.67) 1.25 (0.37 - 4.19) 1.47 (0.36 - 6.05)
Persons without cancer 187 40% (26% - 55%) 44% (35% - 53%) 21% (13% - 30%) 67% (56% - 76%) 0.42 (0.34 - 0.50) 0.52 (0.27 - 1.00) 0.48 (0.22 - 1.03)
GFI Cancer patients 67 40% (16% - 68%) 50% (36% - 64%) 19% (7% - 36%) 74% (57% - 88%) 0.45 (0.30 - 0.60) 0.67 (0.21 - 2.14) 0.50 (0.11 - 2.20)
Persons without cancer 187 42% (28% - 57%) 53% (45% - 62%) 25% (16% - 35%) 72% (62% - 80%) 0.48 (0.40 - 0.56) 0.83 (0.43 - 1.59) 0.89 (0.42 - 1.88)
VES-13 Cancer patients 67 47% (21% - 73%) 54% (40% - 68%) 23% (10% - 41%) 78% (61% - 90%) 0.50 (0.36 - 0.65) 1.02 (0.32 - 3.23) 0.53 (0.10 - 2.83)
Persons without cancer 187 42% (28% - 57%) 53% (45% - 62%) 25% (16% - 35%) 72% (62% - 80%) 0.48 (0.40 - 0.56) 0.83 (0.43 - 1.59) 0.88 (0.40 - 1.92)
Significant OR’s were indicated in bold.
Abbreviations: QoL Quality of Life, aCGA abbreviated Comprehensive Geriatric Assessment, GFI Groningen Frailty Indicator, VES-13 Vulnerable Elders Survey-13, Se sensitivity, Sp specificity, PPV positive predictive value,
NPV negative predictive value, OR odds ratio, 95% CI 95% confidence interval.
aFunctional decline was defined as deterioration one or more domains of ADL and/or IADL compared to baseline.
bDecline in QoL was defined as a difference of ≥ 10 points.
cMultivariate logistic regression: adjusted for age, gender, and number of medicines. For cancer patients we also adjusted for stage, type of cancer, and type of treatment.
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univariate analyses. Furthermore, we found no evidence
for increased risk for decline in QoL, and overall the
sensitivity, specificity and predictive values of the geriat-
ric screening tools were low.
The diagnostic value of geriatric screening tools
The majority of studies on the usefulness of geriatric
screening tools have focused on their ability to identify
patients who might benefit from a full geriatric assess-
ment. Hamaker et al. were the first to systematically
review the diagnostic value of several geriatric screening
tools against a full geriatric assessment in an oncogeria-
tric population [10]. They showed a median sensitivity of
51% for the aCGA, 57% for the GFI, and 68% for the
VES-13. Only for the G8 sensitivity was high (87%). A
recent update of the SIOG recommendations showed
similar results [11]. Decoster et al. also showed that the
sensitivity of the G8 was better compared to other tools,
whereas results for the VES-13 were mixed. The super-
iority of the G8 compared to the VES-13 with respect to
sensitivity was also confirmed by others [32,33]. For
example, a recent large cohort study in France, showed a
sensitivity of 77% for the G8 and 69% for the VES-13
[33]. We agree with the recommendations of Decoster
et al.; “screening tools do not replace a full geriatric
assessment but are recommended in a busy practice in
order to identify those patients in need of a full geriatric
assessment” [11].
In older persons without cancer similar results have
been found as well. For example, a recent systematic re-
view in community-dwelling older people showed a sen-
sitivity of 58% for the GFI [34]. We showed a sensitivity
of 74% for the GFI and 82% for the VES-13 in older
persons without cancer [28].
It was however beyond the scope of the current study
to investigate the diagnostic value of geriatric screening
tools against a full geriatric assessment. In contrast, we
aimed to assess the value of geriatric screening tools to
predict decline in functional status and QoL in a popula-
tion of older (cancer) patients with a good prognosis.
The predictive value of geriatric screening tools
Recently, the predictive value of geriatric screening tools
has received increasing attention. For example, a couple
of larger studies have shown that abnormal scores for
the G8 [13,33,35] and GFI [36] are predictive for mortal-
ity in a population of older cancer patients. However,
data are still sparse and need confirmation by others
(for a recent overview see Decoster et al. [11]).
Predicting functional decline in older cancer patients
To our knowledge, this is the first study to investigate
the ability of the aCGA, GFI and VES-13 to predictfunctional decline in an oncogeriatric population, and
only one study has investigated the predictive value of
the G8 [13]. We found that in older cancer patients with
a relatively good prognosis, neither the G8, nor the
aCGA, GFI, or VES-13 seems to predict functional
decline after one-year follow-up.
Kenis et al. studied the value of the G8 and the Flemish
version of the Triage Risk Screening tool to predict
functional decline after three months [13]. For the G8 and
decline in ADL after three months, they showed a high
sensitivity (84%) and a high negative predictive value
(91%). In contrast, we showed a sensitivity of 64%, and a
negative predictive value of 43% for the prediction of
functional decline after one year of follow-up by the G8.
Our definition of functional impairment and func-
tional decline was very inclusive, namely impairment or
deterioration on at least one domain of ADL or IADL.
However, when functional impairment was disentangled
in impairment on ADL or IADL our results were similar
to those reported by others. For example, we showed
impairment in 51% and 56% of older cancer patients for
ADL and IADL respectively. Similarly, Kenis et al. who
measured functional status before start of treatment in a
comparable population, showed impairment in 51% and
57% of older cancer patients for ADL and IADL respect-
ively [13]. In order to test the influence of our definition
of functional decline, we also calculated sensitivity, spe-
cificity, and positive and negative predictive values for
decline in ADL and IADL separately. This did not
change the interpretation of our results. For example,
for predicting decline in ADL after one year of follow-up
by the G8, sensitivity was 64% and negative predictive
value 60%. It may be possible that geriatric screening
tools are more suitable to predict outcomes such as func-
tional decline on the short term. In this respect, a recent
study showed that specific elements of a geriatric assess-
ment, such as depression and impairment for IADL,
predicted functional decline between the beginning of
chemotherapy and the second cycle [37]. However,
Huisman et al. showed no association between the GFI and
VES-13 and 30-day morbidity after cancer surgery [38].
Predicting functional decline in an older primary care
population
Compared to older cancer patients, the ability of geriat-
ric screening tools to predict functional decline has been
studied more extensively in a general older population
without a history of cancer. We showed that abnormal
scores for the selected geriatric screening tools were
associated with a higher risk of functional decline in an
older primary care population without a history of can-
cer. However, except for the VES-13, this was only true
for univariate analyses and sensitivity was low ranging
from 58% to 67% and an AUC between 0.60 and 0.64.
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are often different from those in an oncogeriatric setting.
Nevertheless, Daniels et al. showed also for these tools,
among which the GFI, that the predictive accuracy was
poor with an area under the curve ranging between 0.54
and 0.67 [39]. From our selected screening tools, only
the GFI and the VES-13 have previously been used in a
general population as well. The G8 and aCGA have been
developed especially for identifying older cancer patients
who might benefit from an entire geriatric assessment.
As such, the predictive validity of these tools has not
been studied in persons without cancer.
For the GFI, Daniels et al. showed a significant associ-
ation (sensitivity 71%, specificity 63%, and AUC 0.67) for
predicting functional decline after one year of follow-up
[39]. In our study, GFI was significantly associated with
functional decline in univariate analyses only. Sensitivity
in our study was lower (58%), but specificity and AUC
were comparable (63% and 0.68 respectively). Other
studies that evaluated the predictive value of the GFI
were cross-sectional, used a different time frame or
other operationalization of the outcome measurement.
For example, Schuurmans et al. showed that the GFI
was more strongly related to self-management abilities
compared to age [40] and Peters et al. showed that GFI
was significantly associated with ADL (data collected
two weeks later) [41].
The VES-13 has been especially developed to identify
community-dwelling vulnerable older people at risk for
functional decline [31], and has been shown to be a good
predictor of functional decline after one year, two years
and even five years [31,42,43]. This was partly confirmed
by our results; abnormal scores on the VES-13 were as-
sociated with functional decline in older persons without
cancer, both in univariate and multivariate analyses.
However, sensitivity, specificity and AUC were still low
(62%, 66%, and 0.64 respectively).
Predicting decline in QoL
QoL is increasingly acknowledged as an important treat-
ment goal, which is for example illustrated by the in-
creasing number of studies that use QoL as a secondary
endpoint [44]. However, to our knowledge, this is the
first study that prospectively evaluates the ability of the
aCGA, G8, GFI, and VES-13 to identify patients at risk
for decline in QoL after one-year follow-up. We showed
that abnormal scores on geriatric screening tools are not
associated with decline in QoL, neither in older cancer
patients, nor in persons without cancer.
In contrast to our results, previous studies have shown a
negative association between mean Qol scores and abnor-
mal scores on geriatric screening tools. A study among
older cancer patients who underwent surgery showed that
GFI scores were significantly associated with QoL at oneand three months after surgery [45]. Although not based
on a screening tool, but on a full geriatric assessment,
Pottel et al. showed in a sample of older patients with head
and neck cancer that vulnerable patients scored signifi-
cantly lower on global QoL compared to fit patients [46].
In a sample of community-dwelling as well as institution-
alized older persons, Peters et al. found a significant
negative association between GFI score and QoL, which
was measured two weeks later [41].
A possible explanation for our differing results is that
we studied the association between the abnormal score
on screening tools and decline in QoL instead of a mean
QoL score. As QoL was already low at time of cancer
diagnosis, only a small proportion of cancer patients
deteriorated even further, which is probably due to a
ceiling effect. In the current study, 23% of older cancer
patients and 30% of persons without cancer experienced
clinically relevant decline in QoL between baseline and
one-year follow-up. Although not statistically significant,
the proportion of cancer patients who experienced a
relevant decline in QoL was smaller compared to per-
sons without cancer. As expected, the mean QoL at
baseline was significantly lower for older cancer patients
compared to persons without cancer (p < 0.01). Similarly
to our results, a Canadian study among cancer patients
aged ≥65 years reported a decline in 23% of patients
between baseline and one year follow-up [47]. A Danish
study showed a decline in 30% of older cancer patients
between cancer diagnosis and six months later [48].
Strengths and limitations of this study
With exception of the G8, this is the first prospective
study to evaluate the value of the aCGA, GFI, and VES-13
to predict functional decline and decline over a one-year
time frame in QoL in older cancer patients. Furthermore,
this is the first prospective study that evaluates the pre-
dictive value of geriatric screening tools in a population of
older cancer patients and in an older primary care popula-
tion without a history of cancer; the identification of
persons at risk for functional decline or decline in QoL is
relevant in both groups. This increases the generalizability
of our results and shows that the predictive value of
selected geriatric screening tools is poor in both groups.
Another important strength of this study is the use of
validated tools, which are commonly used in an oncoger-
iatric population [10].
Nevertheless, this study is also prone to some limita-
tions. Although our selected tools are commonly used in
an oncogeriatric population, these have been less exten-
sively implemented in primary care. Furthermore, for
cancer patients, it was not always possible to interview
patients before start of treatment. However, we do not
believe this influences our results as we showed that our
results for functional status and QoL were similar to
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tients before start of treatment [13,47]. Furthermore, the
proportion of people with an abnormal score at baseline
on the selected geriatric screening tools were compar-
able with those previously reported in cancer patients as
well as a primary care population [11,41]. Another limi-
tation is the relatively small sample size of cancer pa-
tients. For example we only had complete data on QoL
for 67 older cancer patients. As such, it may be possible
that the statistically non-significant results for older can-
cer patients were due to lack of power. Nevertheless, we
showed that our results with respect to sensitivity and
specificity were comparable to others and for QoL we
showed that the operationalization of decline probably
played a roll as well. Loss to follow-up and incomplete
data is a frequent problem in studies among older
patients. In our study, 23% of patients were lost to
follow-up, 6% of patients skipped the data collection at
one-year follow-up, and depending on the variable of
interest between 0 and 22 persons had incomplete data.
However, we do not believe that this affects the reliabil-
ity of our results. First, patients who were excluded from
analyses (due to loss to follow-up or skipping data
collection) were comparable with persons included in
the analyses with respect to baseline characteristics
(see Additional file 1: Table S1). Except for the in- and
excluded cancer patients, the distribution of cancer stage
was different. Second, our results were robust for sensi-
tivity analyses. Results did not change, neither when
missing values for geriatric screening tools were imputed
either as a worst- or best-case scenario, nor when mor-
tality was included as endpoint for functional decline
and decline in QoL (see Additional file 2: Table S2 and
S3). Furthermore, the proportion lost to follow-up is com-
parable with other large health and ageing studies in
Europe. For example 22% loss to follow-up in the English
Longitudinal Study of Ageing (ELSA) [49] and 27% in the
Survey of Health, Ageing and Retirement in Europe
(SHARE) [50]. Moreover, similar to our study, the per-
centage of loss to follow-up remained the same when it
was subdivided to persons who had been diagnosed with
cancer and persons who had never been diagnosed with
cancer [49].
Conclusion
In this study we showed that the ability of the selected
geriatric screening tools to identify patients at risk for
functional decline or decline in QoL after one year is
poor. This was the case for older cancer patients with a
considerable life expectancy as well as older persons
without cancer. Hence, a geriatric screening tool cannot
be relied on in isolation, but they do provide very valu-
able information and may prompt physicians to also
consider different aspects of functioning. These resultsneed to be confirmed, as the number of prospective
studies in an oncogeriatric population is still limited.
Additional files
Additional file 1: Table S1. Baseline population characteristics for
participants included and excluded from analyses. Table S1. shows the
comparison between patients that were included and excluded from
analysis.
Additional file 2: Table S2. Sensitivity analysis: mortality was included
as functional decline or decline in QoL. Table S3. Sensitivity analysis:
missing values were imputed as best and worst case scenario. Table S4.
Sensitivity analysis: women separately. Table S5. Sensitivity analysis:
predicting decline in ADL and IADL separately. Tables S2 – S5. present
the sensitivity analyses. We repeated the analyses by including participants
who died during one-year follow-up, by making a worst- and best-case
scenario with imputing missing values as either a normal or abnormal score,
by repeating the analyses for women separately, and by repeating the
analyses for decline on ADL and IADL separately.
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